The FDA accepted a new drug application for SYD-101 to slow the progression of pediatric myopia and assigned a Prescription Drug User Fee Act date of Oct. 23, according to a press release from Sydnexis.
“There are no FDA-approved pharmaceutical products to treat myopia progression, which is rapidly increasing in incidence and associated with many ocular comorbidities,” Gregory Ostrow, MD, director of pediatric ophthalmology and adult strabismus at Scripps Clinic in San Diego, told Healio. “Ophthalmologists and optometrists are forced to use compounded products now to treat a